{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:44:59Z","timestamp":1793209499369,"version":"4.5.0"},"reference-count":75,"publisher":"American Society of Hematology","issue":"19","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Gene therapy for severe hemophilia A uses an adeno-associated virus (AAV) vector and liver-specific promoters that depend on healthy hepatocyte function to achieve safe and long-lasting increases in factor VIII (FVIII) activity. Thus, hepatocyte health is an essential aspect of safe and successful gene therapy. Many people living with hemophilia A have current or past chronic hepatitis C virus infection, metabolic dysfunction\u2013associated steatosis or steatohepatitis, or other conditions that may compromise the efficacy and safety of AAV-mediated gene therapy. In addition, gene therapy may induce an immune response to transduced hepatocytes, leading to liver inflammation and reduced FVIII activity. The immune response can be treated with immunosuppression, but close monitoring of liver function tests and factor levels is necessary. The long-term risk of hepatocellular carcinoma associated with gene therapy is unknown. Routine screening by imaging for hepatocellular carcinoma, preferable every 6\u00a0months, is essential in patients at high risk and recommended in all recipients of hemophilia A gene therapy. This paper describes our current understanding of the biologic underpinnings of how liver health affects hemophilia A gene therapy, and provides practical clinical guidance for assessing, monitoring, and managing liver health both before and after gene therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013059","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T18:19:12Z","timestamp":1717697952000},"page":"5203-5212","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Optimizing liver health before and after gene therapy for hemophilia A"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"first","affiliation":[{"name":"1Division of Hematology\/ Oncology, Department of Medicine, University of Pittsburgh Medical Center, and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8857-108X","authenticated-orcid":false,"given":"Henry","family":"Mead","sequence":"additional","affiliation":[{"name":"2BioMarin Pharmaceutical Inc, San Rafael, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-2370","authenticated-orcid":false,"given":"Ype P.","family":"de Jong","sequence":"additional","affiliation":[{"name":"3Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-1958","authenticated-orcid":false,"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-0790","authenticated-orcid":false,"given":"Andrew D.","family":"Leavitt","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine and Medicine, University of California San Francisco Hemophilia Treatment Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1350-0293","authenticated-orcid":false,"given":"Brian","family":"Long","sequence":"additional","affiliation":[{"name":"2BioMarin Pharmaceutical Inc, San Rafael, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-0879","authenticated-orcid":false,"given":"Diane J.","family":"Nugent","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Division of Hematology Oncology, Children\u2019s Hospital of Orange County, University of California Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6116-5453","authenticated-orcid":false,"given":"Denise E.","family":"Sabatino","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-4146","authenticated-orcid":false,"given":"Sylvia","family":"Fong","sequence":"additional","affiliation":[{"name":"2BioMarin Pharmaceutical Inc, San Rafael, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-6322","authenticated-orcid":false,"given":"Annette","family":"von Drygalski","sequence":"additional","affiliation":[{"name":"8Department of Medicine, University of California, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-9656","authenticated-orcid":false,"given":"Christopher E.","family":"Walsh","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0854-6249","authenticated-orcid":false,"given":"Bruce A.","family":"Luxon","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Division of Gastroenterology, Medstar Washington Hospital Center and Medstar Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"11","key":"2024100815203302000_bib1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024100815203302000_bib2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024100815203302000_bib3","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","volume":"21","author":"O'Mahony","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024100815203302000_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"issue":"14","key":"2024100815203302000_bib5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","article-title":"Gene therapy in hemophilia A: a cost-effectiveness analysis","volume":"2","author":"Machin","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2024100815203302000_bib6","first-page":"667","article-title":"The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors","volume":"27","author":"Agboola","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"2","key":"2024100815203302000_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jhep.2023.10.029","article-title":"Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists","volume":"80","author":"M\u00fccke","year":"2024","journal-title":"J\u00a0Hepatol"},{"issue":"26","key":"2024100815203302000_bib8","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1182\/bloodadvances.2017009878","article-title":"Hemophilia gene therapy comes of age","volume":"1","author":"George","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"2024100815203302000_bib9","doi-asserted-by":"crossref","first-page":"e12586","DOI":"10.1002\/rth2.12586","article-title":"The intersection of vector biology, gene therapy, and hemophilia","volume":"5","author":"Lisowski","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2024100815203302000_bib10","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"issue":"1","key":"2024100815203302000_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/JVI.80.1.426-439.2006","article-title":"Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype","volume":"80","author":"Grimm","year":"2006","journal-title":"J\u00a0Virol"},{"key":"2024100815203302000_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"2024100815203302000_bib13","volume-title":"Safety and Efficacy of Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: An Update From 4 Years After Treatment. Thrombosis & Hemostasis Summit","year":"2024"},{"issue":"5","key":"2024100815203302000_bib14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"issue":"21","key":"2024100815203302000_bib15","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2024100815203302000_bib16","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1182\/blood-2009-02-206979","article-title":"Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver","volume":"113","author":"Madeira","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2024100815203302000_bib17","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2014-02-554501","article-title":"Murine coagulation factor VIII is synthesized in endothelial cells","volume":"123","author":"Everett","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2024100815203302000_bib18","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood-2014-02-555151","article-title":"A\u00a0conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII","volume":"123","author":"Fahs","year":"2014","journal-title":"Blood"},{"key":"2024100815203302000_bib19","doi-asserted-by":"crossref","first-page":"10760296221128294","DOI":"10.1177\/10760296221128294","article-title":"Prevalence of non-alcoholic fatty liver disease and associated factors in patients with moderate or severe hemophilia: a multicenter-based study","volume":"28","author":"Shen","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"2024100815203302000_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.14607","article-title":"Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: a national inpatient sample study","volume":"28","author":"Yang","year":"2022","journal-title":"Haemophilia"},{"issue":"17","key":"2024100815203302000_bib21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024100815203302000_bib22","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in\u00a0vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J\u00a0Virol"},{"issue":"2","key":"2024100815203302000_bib23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"2024100815203302000_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.15189","article-title":"Mortality in congenital hemophilia A - a systematic literature review","volume":"19","author":"Hay","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"suppl 2","key":"2024100815203302000_bib25","first-page":"S11","article-title":"Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status","volume":"90","author":"Curtis","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"2024100815203302000_bib26","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1172\/JCI115482","article-title":"Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs","volume":"88","author":"Allain","year":"1991","journal-title":"J\u00a0Clin Invest"},{"issue":"8698","key":"2024100815203302000_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0140-6736(90)91124-S","article-title":"Hepatitis C antibody and chronic liver disease in haemophilia","volume":"335","author":"Makris","year":"1990","journal-title":"Lancet"},{"issue":"24","key":"2024100815203302000_bib28","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024100815203302000_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2516.2010.02366.x","article-title":"Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia","volume":"17","author":"Ragni","year":"2011","journal-title":"Haemophilia"},{"issue":"7","key":"2024100815203302000_bib30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/319273","article-title":"Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection","volume":"183","author":"Ragni","year":"2001","journal-title":"J\u00a0Infect Dis"},{"issue":"9","key":"2024100815203302000_bib31","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V85.9.2337.bloodjournal8592337","article-title":"Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups","volume":"85","author":"Ragni","year":"1995","journal-title":"Blood"},{"issue":"8","key":"2024100815203302000_bib32","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2022008948","article-title":"Valoctocogene roxaparvovec gene transfer in participants with HIV","volume":"7","author":"Ragni","year":"2023","journal-title":"Blood Adv"},{"key":"2024100815203302000_bib33","author":"Medical and Scientific Advisory Council","year":"2016"},{"issue":"5","key":"2024100815203302000_bib34","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis regression after eradication of hepatitis C virus: from bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"2024100815203302000_bib35","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"2024100815203302000_bib36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"R1","key":"2024100815203302000_bib37","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","article-title":"Advances and challenges for hemophilia gene therapy","volume":"28","author":"Batty","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2024100815203302000_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"issue":"3","key":"2024100815203302000_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"2","key":"2024100815203302000_bib40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"issue":"3","key":"2024100815203302000_bib41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"issue":"6","key":"2024100815203302000_bib42","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"7961","key":"2024100815203302000_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","article-title":"Adeno-associated virus 2 infection in children with non-A-E hepatitis","volume":"617","author":"Ho","year":"2023","journal-title":"Nature"},{"issue":"24","key":"2024100815203302000_bib44","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.3390\/ijms222413578","article-title":"Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms","volume":"22","author":"Sirbe","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2024100815203302000_bib45","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","article-title":"Biochemical, immunological, and in\u00a0vivo functional characterization of B-domain-deleted factor VIII","volume":"81","author":"Pittman","year":"1993","journal-title":"Blood"},{"issue":"2","key":"2024100815203302000_bib46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"issue":"47","key":"2024100815203302000_bib47","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2024100815203302000_bib48","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol Ther"},{"key":"2024100815203302000_bib49","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024100815203302000_bib50","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024100815203302000_bib51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"2024100815203302000_bib52","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","volume":"30","author":"Butterfield","year":"2022","journal-title":"Mol Ther"},{"issue":"4","key":"2024100815203302000_bib53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"2024100815203302000_bib54","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"2024100815203302000_bib55","first-page":"425","article-title":"Rare genomic integrations of AAV5-hFVIII-SQ occur without evidence of clonal activation or gene-specific targeting [abstract]","volume":"29","author":"Sullivan","year":"2021","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"2024100815203302000_bib56","article-title":"Frequency, location and nature of AAV vector insertions after long-term follow up of FVIII transgene delivery in a hemophilia A dog model [abstract]","volume":"4","author":"Batty","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2024100815203302000_bib57","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","author":"Greig","year":"6  2023","journal-title":"Nat Biotechnol"},{"issue":"10","key":"2024100815203302000_bib58","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"issue":"8","key":"2024100815203302000_bib59","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"issue":"17","key":"2024100815203302000_bib60","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2024100815203302000_bib61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"2024100815203302000_bib62","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.ymthe.2023.08.013","article-title":"Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"31","author":"Retson","year":"2023","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"2024100815203302000_bib63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.13915","article-title":"Integration and the risk of liver cancer-Is there a real risk?","volume":"31","author":"Kasimsetty","year":"2024","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"2024100815203302000_bib64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"2024100815203302000_bib65","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"2024100815203302000_bib66","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver Electronic address easloffice@easlofficeeu","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"2024100815203302000_bib67","author":"Medical and Scientific Advisory Council","year":"2023"},{"issue":"2","key":"2024100815203302000_bib68","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtha.2022.11.026","article-title":"Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists","volume":"21","author":"Miesbach","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024100815203302000_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2024100815203302000_bib70","first-page":"25","volume-title":"Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection","author":"World Health Organization","year":"2015"},{"issue":"5","key":"2024100815203302000_bib71","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2024100815203302000_bib72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12876-022-02290-1","article-title":"Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups","volume":"22","author":"Sugiyama","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"2024100815203302000_bib73","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"2024100815203302000_bib74","first-page":"401","article-title":"Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis","volume":"70","author":"Nathani","year":"2021","journal-title":"Gut"},{"issue":"2","key":"2024100815203302000_bib75","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J\u00a0Hepatol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5203\/2245490\/blooda_adv-2024-013059-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5203\/2245490\/blooda_adv-2024-013059-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:03:03Z","timestamp":1728403383000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5203\/516370\/Optimizing-liver-health-before-and-after-gene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":75,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013059","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}